



University of Dundee

Improving effective contraception uptake through provision of bridging contraception within community pharmacies

Patterson, Susan; McDaid, Lisa M.; Saunders, Kristina; Battison, Claire; Glasier, Anna; Radley, Andrew

Published in:
BMJ Open

DOI:
[10.1136/bmjopen-2021-057348](https://doi.org/10.1136/bmjopen-2021-057348)

Publication date:
2022

Licence:
CC BY

Document Version
Publisher's PDF, also known as Version of record

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Patterson, S., McDaid, L. M., Saunders, K., Battison, C., Glasier, A., Radley, A., Stephenson, J. M., Johnstone, A., Morelli, A., Sally, D., Stewart, N., & Cameron, S. T. (2022). Improving effective contraception uptake through provision of bridging contraception within community pharmacies: findings from The Bridge-it Study process evaluation. *BMJ Open*, 12(2), [e057348]. <https://doi.org/10.1136/bmjopen-2021-057348>

General rights






Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

BMJ Open Improving effective contraception uptake through provision of bridging contraception within community pharmacies: findings from the Bridge-it Study process evaluation

Susan Patterson ¹, Lisa McDaid ^{1,2}, Kristina Saunders,³ Claire Battison,⁴ Anna Glasier,⁵ Andrew Radley ^{6,7}, Judith M Stephenson,⁸ Anne Johnstone,⁵ Alessandra Morelli ⁹, Deirdre Sally,¹⁰ Nicola Stewart,¹⁰ Sharon Tracey Cameron ^{5,11}

To cite: Patterson S, McDaid L, Saunders K, *et al*. Improving effective contraception uptake through provision of bridging contraception within community pharmacies: findings from the Bridge-it Study process evaluation. *BMJ Open* 2022;**12**:e057348. doi:10.1136/bmjopen-2021-057348

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2021-057348>).

Received 12 September 2021
Accepted 06 January 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Susan Patterson;
susan.patterson@glasgow.ac.uk

ABSTRACT

Objective To present process evaluation results from the Bridge-it Study, a pragmatic cluster randomised cross-over trial to improve effective contraception uptake through provision of the progestogen only pill (POP) plus sexual and reproductive health (SRH) clinic rapid-access to women presenting to community pharmacies for emergency contraception (EC).

Research design and methods A multimethod process evaluation was conducted to assess intervention implementation, mechanisms of change and contextual factors. Data were gathered from screening logs (n=599), observations of pharmacist training, analysis of data from 4-month follow-up questionnaires (n=406), monitoring of contemporaneous events and qualitative interviews with 22 pharmacists, 5 SRH clinical staff and 36 study participants in three participating UK sites in Lothian, Tayside and London.

Results The intervention was largely delivered as intended and was acceptable. Pharmacists', SRH clinical staff and participants' accounts highlighted that providing a supply of POP with EC from the pharmacy as routine practice may have positive impacts on contraceptive practices in the short term, and potentially longer term. Key mechanisms of change included ease of access, increased awareness of contraception and services, and greater motivation and perceptions of self-efficacy. Few participants took up the offer to attend an SRH service (rapid-access component), and existing barriers within the SRH context were apparent (eg, lack of staff). Participant accounts highlight persistent barriers to accessing and using routine effective contraception remain.

Conclusions Implementation appeared to be acceptable and feasible, highlighting the potential for provision of POP within EC consultations as routine practice in community pharmacies. However, lack of engagement with the rapid access component of the intervention and existing barriers within the SRH context suggest that signposting to SRH services may be sufficient. Wider implementation should consider ways to address key implementation challenges to increase effectiveness and sustainability, and

Strengths and limitations of this study

- The Bridge-it study process evaluation combined qualitative and quantitative methodologies to provide comprehensive and robust insights into implementation of the intervention, mechanisms of change and important contextual factors.
- Due to participants being followed up 4-month postintervention, and qualitative interviews taking place at one time point, we are unable to comment on continuation of the chosen contraceptive method and longer-term implementation of the service.
- While purposive sampling was employed to ensure providers and participants recruited for interviews were diverse, the generalisability of findings are limited to accounts from those who agreed to take part in the trial, and to those who agreed to be interviewed.
- Providers and study participants were asked to reflect on experiences up to 6 months previously, which may have impacted on recall.
- Due to limited use of the rapid access component and difficulties recruiting sexual and reproductive health (SRH) clinical staff for interview, accounts of experiences within the SRH context were limited; additionally, due to practical reasons, we were unable to observe implementation of the intervention within the pharmacy or SRH context, making assessing fidelity of the intervention difficult.

to overcome persistent barriers to accessing and using effective contraception.

Trial registration number ISRCTN70616901.

INTRODUCTION

Unintended pregnancy remains a public health issue within the UK, with abortion rates in 2020 reaching the highest numbers recorded since records began (13.4 per

1000 women (aged 15–44) in Scotland¹; 18.2 per 1000 women (aged 15–44) in England and Wales²). Additional outcomes of unintended pregnancy include miscarriage, ectopic pregnancy, unwanted or mistimed birth, all with the potential to have adverse impacts on maternal and child health.³ Oral emergency contraception (EC) can be used to prevent unintended pregnancy, and is typically accessed through community pharmacies.^{4 5} Guidance from the Faculty of Sexual and Reproductive Health (SRH) emphasises the importance of rapid access to ongoing contraception after EC,⁶ but many face barriers to accessing further contraception such as difficulties accessing general practitioner (GP) appointments and contraceptive services, fuelled by sexual health service funding cuts, and more recently exacerbated by the coronavirus pandemic.⁷ Within this context, pharmacies present a promising venue for increasing access to contraception, with long opening hours and wide geographical coverage,^{8 9} but until recently, were only able to provide condoms without a prescription. In July 2021, progestogen-only contraceptive pills were approved for sale over the counter in community pharmacies in the UK¹⁰), and while this represents a step forward in provision, the requirement to pay may further increase already-evident inequalities in access and outcomes.^{1 2} Taking this into consideration, in November 2021, following the successful Bridge-it study trial,¹¹ women in Scotland are now able to obtain a 3-month supply of the progestogen-only pill free of charge from within community pharmacies.¹²

The Bridge-it Study was a pragmatic cluster randomised cross-over trial designed to determine the effectiveness of a bridging contraceptive service within community pharmacies in increasing uptake of effective contraception. The intervention consisted of the provision of a 3-month supply of the progestogen only pill (POP) (75 µg desogestrel/day) after EC (levonorgestrel 1.5 or 3 mg) at no cost within EC consultations, alongside a study card which on presentation at participating SRH services enabled rapid access to appointments for advice and provision of ongoing contraception. The card provided information on the location and opening times of the participating SRH clinics (three in London, two in Tayside and one in Lothian). In the control arm in which women were not provided with the POP, participants were advised to attend their GP/SRH service or usual contraceptive provider for contraception after EC (standard care). Participants were followed up at 4 months, either by telephone interview with a research nurse, or by self-administered questionnaire via email, and asked about contraceptive use, their experience within the pharmacy, and use of the rapid access card (intervention group). In total, 29 UK pharmacies in London (n=14), Lothian (n=12) and Tayside (n=3) participated in the study, and recruited 636 participants (intervention n=316; control n=320). Analysis of the main outcome of the study demonstrated the effectiveness of the intervention, with a greater proportion of women using effective contraception at 4-month follow-up within

the intervention group (58.4% SD 21.6) compared with the control group (40.5% SD 23.8).¹¹ Full details on the trial protocol and outcomes are reported elsewhere.^{11 13}

This paper reports a multi-method process evaluation of the Bridge-it intervention, included to assess implementation, mechanisms of change and context (eg, external factors that may influence implementation and effectiveness), in order to better understand the overall intervention outcomes and shed light on reasons why the intervention was effective (or not).¹⁴ The process evaluation was underpinned by a conceptual framework, which incorporated a range of causal assumptions, and acknowledgement of the potential impact of contextual factors on achievement of key outcomes (see figure 1). Formative research highlighting desire among women presenting for EC at community pharmacies for access to ongoing contraception through community pharmacies, and existing barriers to access faced in more traditional settings,^{15 16} informed the design of the process evaluation, which aimed to understand:

- ▶ Was the intervention implemented as planned?
- ▶ How did the delivered intervention impact on contraceptive practices?
- ▶ How did the local and broader context affect implementation and outcomes?

Given the recent changes in POP availability within pharmacies in Scotland, this paper is timely, and will help to shed light on key issues and how wider implementation of the service within community pharmacies may be optimised.

METHODS

The process evaluation used an evaluation framework to allow the systematic synthesis of data on implementation, perceived mechanisms of change, and the impact of context on implementation and outcomes (see figure 1). The funder had no role in the intervention or evaluation design.

Data sources and analysis

Qualitative interviews with pharmacists, SRH clinical staff and participants

Qualitative data were collected from those delivering the intervention (pharmacists and SRH clinical staff), and those receiving it (Bridge-it Study participants). Semi-structured qualitative interviews were conducted by telephone by the process evaluation research assistants (SP and KS), who were not involved in the development or implementation of the main trial, and had no relationship with providers or study participants. Topic guides were specific to each group (see online supplemental data file 1), exploring issues such as acceptability of the intervention, experiences of delivering the intervention or of receiving it, impacts on contraceptive practices, and contextual issues relevant to implementation and outcomes. Consent was obtained, interviews were audiotaped, transcribed verbatim, anonymised and




Figure 1 The Bridge-it study process evaluation framework. EC, emergency contraception; POP, progestogen only pill; SRH, sexual and reproductive health.

uploaded to QSR NVivo V.10 for analysis. Data analysis was undertaken using Framework Analysis, where data are coded, indexed and charted systematically to facilitate synthesis of key themes.¹⁷ The thematic coding framework was developed by the process evaluation team (SP, KS and LM), largely using a deductive approach guided by the research questions, process evaluation framework and topic guide, but also shaped by new themes generated through the familiarisation stage and open coding. This thematic coding framework was used to systematically code and chart the data using constant comparison to ensure all perspectives were represented, and enabled further analysis to shed light on commonalities and differences by themes within and across the data. The framework analysis method was particularly useful for this multi-method process evaluation, as non-interview data could easily be incorporated within matrices (eg, fieldnotes; observational data).

Research nurses asked participants for consent to be contacted for a qualitative interview at the end of the 4-month follow-up questionnaire, and interviews were conducted between November 2018 and October 2019. Purposive sampling was used aiming to recruit a representative and diverse sample, with participants sampled by area, age, ethnicity, use of the study POP, and attendance at SRH. However due to difficulties in recruiting, we approached all participants who agreed to be contacted for interview. In total, 36 intervention participants were interviewed (figure 2), and participant characteristics

were largely representative of the main study sample,¹¹ with similar characteristics to EC users nationally.^{15 16} Intervention participants were aged 18–37, and the majority were under 24 (n=21) and described themselves as white (n=29). Many had used EC previously (n=17), over half used all three packets of POP (n=21) and five had attended the SRH clinic. Almost half (n=16) were using a POP or another effective contraceptive method at the time of interview. Most of the interviews were conducted with participants in Edinburgh, reflecting the greater number of participants recruited to the study within Lothian (recruitment began earlier and included more larger chain pharmacies with high EC dispensing rates), as well as lower response to the 4-month follow-up questionnaire, and willingness to be contacted to take part in a qualitative interview among study participants in London. On average interviews lasted between 30 and 60 min.

During training sessions, pharmacists were presented with information about the process evaluation interviews, and later contacted by the Trial manager or research nurse to ask if they were willing to be contacted for an interview by the process evaluation research assistant. The interviews were conducted between July 2018 and July 2019, with most taking place once recruitment had ended within their particular pharmacy. In total, 22 pharmacists were interviewed, 12 from Lothian, three from Tayside and seven from London. The aim had been to interview one pharmacist from each participating pharmacy. The main pharmacies not represented (n=7) are

Bridge-it sites and recruitment




Figure 2 Breakdown of main study and process evaluation (PE) recruitment and sites. SRH, sexual and reproductive health

based in South London and it had not been possible to conduct interviews before the study was discontinued. Interviews typically lasted 30–45 min.

SRH clinical staff were contacted by the research nurses and asked if they were willing to be contacted for interview, with subsequent interviews conducted between May and October 2019, approximately 4–6 months after study recruitment had ended to allow time for experience of participants attending their service. Five SRH clinical staff were interviewed within three of the participating NHS sites (two in Lothian, two in Tayside and one in London). We had originally aimed to interview 3–4 staff members from each service, however, recruitment was challenging, particularly due to low Bridge-it participant attendance at SRH clinics. Interviews typically lasted 30–45 min.

Researcher field notes and meeting minutes

Fieldwork reflections were recorded and meeting minutes analysed to explore factors that may have influenced consistency or quality of data and implementation.

Monitoring of pharmacy recruitment and observations of training

Pharmacy recruitment was monitored using a standardised form to record factors relating to pharmacy selection, including reasons for inclusion/exclusion (eg, location; high EC distribution); and reasons for acceptance/refusal (eg, lack of interest; high workloads) (see online supplemental data file 2). Thirteen Bridge-it training sessions for pharmacists were observed by a research assistant in Scotland, and all intervention and training materials were reviewed. A training observation proforma (see online supplemental data file 3) was completed by the research assistant, with particular attention paid to the way key intervention mechanisms were presented to, and apparently understood by, pharmacists. Written observational data were transcribed into Microsoft word, thematic analysis conducted guided by the proforma, and descriptive summaries written.

Quantitative data

The process evaluation drew on the baseline questionnaire (demographic details; reproductive history; previous contraceptive use), the 4-month follow-up questionnaire (contraceptive use; experience in pharmacy; use of rapid access card; n=406, 64% of participants) (see online supplemental data file 4), and pharmacist screening logs (n=599), detailing reasons for exclusion/declining. Data were analysed descriptively (software package SPSS V.25).

Synthesis of multiple data sources

All process evaluation data were analysed prior to reporting of trial outcome data to minimise bias in interpretation, and the process evaluation team regularly discussed analysis progress for each source of data collection, allowing any issues encountered to be resolved. Following independent analysis of each data source, the data were synthesised to address the three key research questions relating to implementation, mechanisms of impact and the role of context. An analytical integration matrix was

created to compare findings from each stage (see online supplemental data file 5). Analysis addressed complementary findings from each source of data and drew out synergistic interpretations to facilitate a broader holistic picture of how the intervention worked in practice.

Patient and public involvement

Members of the participating Edinburgh SRH service patient and public involvement group were service users and contributed to the design of the Bridge-it study process evaluation through reviewing and commenting on study documentation. Members participated in the trial steering committee to assist with oversight of the study.

RESULTS

This section presents key findings relating to implementation, mechanisms of impact, and the influence of contextual factors on implementation. Additional findings for each measure are presented in online supplemental data files 6, 7 and 8.

Implementation: acceptability and fidelity

The intervention was acceptable to pharmacists who saw it as an important way to improve access to contraception and help reduce repeat EC use and unwanted pregnancy rates: ‘it shows that people are taking the issue of unwanted pregnancy seriously and they’re trying to improve, you know, the accessibility of services to women’ (Pharmacist 18, Lothian). Most pharmacists interviewed were positive about the training they received and indicated that it prepared them to deliver the intervention as planned. Participants’ accounts of their experiences within participating pharmacies suggest that fidelity of delivery was largely achieved, with most describing positive and informative encounters, although just over a quarter of intervention participants (54/198) could not recall being given a ‘rapid access card’ for an appointment at the study SRH clinic.¹¹ Those who attended SRH services described less positive experiences, including services being too busy and a lack of awareness among staff. For more detail on participants’ experiences within the pharmacy and SRH context, and other relevant fidelity data, see online supplemental data file 6.

Mechanisms of impact

Overcoming barriers to accessing routine contraception

Pharmacists’, SRH clinical staff and participants’ accounts suggest that bridging as a practice within pharmacies may have positive impacts on women’s contraceptive awareness and use in the short, and potentially in the longer term. Many participants discussed how being approached within the pharmacy and being offered a bridging method acted as a necessary prompt to change contraceptive practices, as typified by Participant 10 (Lothian): ‘It made me kind of realise that it was time to go on one and that it was something I did need to do’. This reinforces

enthusiasm from pharmacists within training sessions and during interviews for the EC consultation as an opportune moment to intervene, and how offering bridging could potentially disrupt repeat EC use, which was viewed as a persistent issue within some community pharmacies.

Many participants emphasised the pharmacy setting in particular as being pivotal to overcoming barriers faced in accessing contraception, some of them personal, including lack of time and embarrassment and some structural, such as difficulties accessing healthcare appointments within traditional settings:

I thought it was really good actually, because yes, usually it's like you have to make an appointment with your GP and maybe, like, if you live in a busy area it can be a couple of weeks that you have to wait, you know, so it was just quite nice being able to go into the pharmacy and, you know, get a longer term solution, if that makes sense (Participant 17, Lothian)

Similarly, pharmacists and SRH clinical staff highlighted the accessibility and convenience of pharmacies as pivotal in overcoming such barriers, particularly for young people and students: 'A lot of people that actually say, yes, they've been wanting to go on contraception for a long time but they didn't have the time or they can't make the time to go to a sexual health clinic' (Pharmacist 20, London).

While ease of access seemed to be a key mechanism of impact, analysis of screening log data and pharmacist interview data did highlight the ingrained nature of such barriers, with lack of time and potential embarrassment noted as key barriers to participation in the study. Pharmacists discussed a sense of rush common to EC consultations, fuelled by embarrassment, which impacted on participation:

I expect, embarrassment, that they just wanted to come in and out, you know, we are talking about something that people feel embarrassed about, they just want to come in, swallow the tablet, get out, forget the whole thing ever happened' (Pharmacist 8, Tayside)

As well as issues of time and embarrassment, narratives of resistance within EC consultations to take the specific contraceptive offered, or hormonal contraception more generally were also commonly mentioned as barriers to participation: 'I had a few people who just didn't really like the sound of hormones' (Pharmacist 17, Tayside). Such barriers may have implications relating to wider uptake of this service within pharmacies, shedding insight into reasons why some chose not to participate in the study.

Increased awareness, confidence and self-efficacy

Participants described other benefits of the intervention relating to the information provided within the pharmacy, including greater awareness of contraception and contraceptive services: 'I found out more about it [contraception]. I've got more knowledge of that type of stuff now so that's one of the positive things, I guess'

(Participant 9, London). For some, this increased awareness resulted in improved confidence in accessing and using contraception:

It's meant that I'm on the pill, I've got that sorted, I know that I can go to the pharmacy to get advice, I hopefully won't be needing the emergency contraception again, but I know that I can get it there if, for whatever reason, I need it. Yeah, I think, it's probably given me a bit more confidence with it as well. (Participant 36, Tayside)

Participants' accounts drew attention to some of the mechanisms of change: viewing contraception as accessible, and increased awareness, confidence and self-efficacy, leading to potentially healthier behaviours and attitudes towards risk. This suggests that the intervention likely prompted participants to think more about their sexual health and longer-term contraception, as well as raising awareness of available contraceptive services.

Facilitators of, and barriers to, continued uptake of routine contraception

It is important to shed light on why the intervention worked for some, and not for others. As reported within the outcomes paper,¹¹ more than half (112/198) of intervention participants were on effective contraception at 4-month follow-up, and 16 of the participants interviewed described being on POP, or another effective method, after recruitment into the study (including previous non-users and past-users with negative experiences on other forms of hormonal contraception). Those who remained on effective contraception tended to find the process of accessing further contraception from their GP/SRH clinic straightforward, and reported no obvious side effects from POP:

I don't feel that there has been any side-effects, like of like up and down moods or mood swings that some other women get on different pills, which is very positive (Participant 1, Lothian).

Another facilitator of continued POP use seemed to be familiarity with oral contraception: 'At the moment I do feel happy on it and it's convenient, I'm used to taking the pill, and my friends are like, 'oh coil is so easy because you don't have to think about it', but I'm used to it' (Participant 18, Lothian).

While many participants had positive experiences of taking part in the Bridge-it study, and were on regular contraception at 4-month follow-up, just under half of all intervention participants were not on contraception at 4-month follow-up (n=88/198).¹¹ Data from the 4-month follow-up survey and participant interviews highlighted common reasons, including not being currently sexually active, side effects concerns, and difficulty arranging or finding the time to attend an appointment to access further contraception.¹¹ In particular, a quarter of intervention participants (n=40/158) discontinued POP due to side effects, with interview participants describing a range of adverse side effects experienced including

spotting, prolonged bleeding, skin problems, poor mental health and mood changes, headaches, weight gain, lowered libido and nausea. The most common side effect mentioned by interview participants were spotting and prolonged bleeding, typified by participant 12 (Lothian): ‘There was blood every day and not much but enough to be annoying, if you know what I mean. So that’s why I only took one packet and then I stopped because I was just like I can’t’. Prior to taking part in the Bridge-it study, 22 of the interview participants attributed not being on contraception at entry to the study to previous negative contraceptive side effects, highlighting the persistent difficulties faced relating to well-being.

For some, not being able to continue accessing POP through the pharmacy acted as a barrier: ‘And if I could just...because I don’t want to have to book an appointment at the GP, you know...if I could just go to the pharmacy and get something I probably would have done it (Participant 22, Lothian). As well as difficulties accessing appointments at GP/SRH clinics, participants’ highlighted potential embarrassment and stigma related to attending SRH clinics as a barrier to the rapid access component of the intervention: ‘I think I would rather go to the GP, but only because I feel like it is a little bit of a taboo to say I’m going to the sexual clinic’ (Participant 27, Lothian). Consistent with these concerns, very few intervention participants attended their local SRH clinic (17%, n=52), and the majority who accessed more POP/alternatives did so via their GPs, suggesting that the incorporation of SRH clinics as an option for seeking ongoing contraception added little to the intervention.¹¹ While overcoming initial access barriers, participants’ accounts highlight that providing a limited supply of POP from the pharmacy and offering rapid access to SRH services did not always succeed in overcoming long-term, recurring barriers to effective contraceptive use.

Context

Participating pharmacies: competing priorities and staffing issues

A range of cross-cutting challenges to implementation of the intervention emerged. Pharmacists highlighted existing contextual challenges, such as high workloads, expanding roles, competing priorities and staff shortages: ‘it never feels like you have enough people’ (Pharmacist 12, Lothian). These existing challenges influenced delivery of the Bridge-it Study in practice, contributing to de-prioritisation of participant screening at busy times and slow recruitment rates: ‘there were a few times I possibly could have done an intervention but I didn’t because I knew my queue was too big’ (Pharmacist 7, Lothian). Pharmacists highlighted the added burden of the research context (eg, study paperwork) as well as the additional required Patient Group Direction (PGD) for the POP, extending EC consultations by approximately 15–20 min. However, pharmacists tended to be positive about embedding a bridging service within everyday practice: ‘the paperwork aspect [research-related] doesn’t fit in because it’s quite time consuming, but the actual clinical aspect and the

reason behind it makes a lot of sense’ (Pharmacist 14, London). While existing challenges and pressures related to services currently provided within pharmacies should be considered in wider implementation, the provision of bridging appeared to be feasible and acceptable within the community pharmacy context, with the majority of concerns typically related to the additional research burden of the intervention.

Participating SRH clinics: funding cuts and changing service provision

SRH clinical staff described continually trying to manage priorities to cope with staff shortages, funding cuts and changing service provision: ‘You know, we’re constantly trying to juggle, and constantly trying to desperately figure out if we take somebody off this clinic then maybe we could cover that clinic...’ (SRH staff 1, Lothian). Accounts highlighted the reshaping of services to accommodate limited funding and resources, with two study sites moving to triaging of all patients, and from walk-in to priority access clinics. Most described an increased focus on young people’s services, and a move away from routine contraception provision to a focus on more specialised services: ‘Because obviously we were providing the more specialist stuff, whereas people that would be looking just for routine contraception would be encouraged to attend their GPs, rather than come to the specialist service, just because the lack of capacity’ (SRH staff 3, Tayside). This had potential implications relating to the implementation of the Bridge-it Study, and concerns were raised relating to services having the resources to cope with rapid access, and the lack of fit with current practice priorities. Some worried that this may have resulted in Bridge-it participants being missed or turned away: ‘And although the nurses were trying to get the information from patients if they had been involved in the Bridge-it study, if the patient did not specifically explain that they probably wouldn’t have been able to get into the clinic that easily’ (SRH staff 2 Tayside). Such concerns were founded, with some participants advised to instead attend their GP. A lack of fit with existing service provision may impact on implementation and raises issues around wider implementation in this format. Changing service provision, combined with lack of engagement with the rapid access component of the intervention suggests that signposting to SRH services may be sufficient and more realistic.

DISCUSSION

Why did the intervention work?

The findings from this multisource process evaluation confirmed our hypothesis that providing access to effective bridging contraception through provision within community pharmacies and signposting to local contraceptive services facilitates uptake of ongoing effective contraception, as highlighted within the outcomes paper.¹¹ Positive impacts on participants’ contraceptive practices were evident, with the convenience and



accessibility of pharmacies appearing to be pivotal in overcoming well-established access barriers to contraception.^{18 19} This adds to the growing literature emphasising the accessibility of community pharmacies, and enthusiasm for the pharmacy as an option for contraceptive service provision.^{8 16 20} The process evaluation shed light on other mechanisms of change highlighted in previous studies.^{19 21 22} These included increased awareness of contraception and contraceptive services, motivation, and perceptions of self-efficacy, leading to potentially healthier behaviours and confidence in managing sexual risk-taking.

Despite existing challenges within the pharmacy and SRH provider context, bridging of POP as a practice within the community pharmacy setting seemed to be welcomed by pharmacists, SRH clinical staff and participants. Accounts emphasised the acceptability of the intervention and existing demand for pharmacy provision of routine contraception, indicating alignment of intervention design and patient need. This suggests that bridging of POP as a practice within community pharmacies is acceptable and feasible and has potential to be widely implemented and successfully embedded within routine practice. A lack of engagement with the rapid access component of the intervention and changing SRH service provision suggest that signposting to SRH services may be sufficient in wider implementation.

How do we optimise wider implementation and improve outcomes?

As a result of the Bridge-it study trial success, bridging as a practice has been implemented within community pharmacies in Scotland.¹² It is vital to address implementation challenges, and work to alleviate persistent barriers to accessing and using effective contraception to optimise effectiveness and sustainability of the intervention in practice. To optimise uptake of bridging within the pharmacy context, it is important to acknowledge barriers to participation encountered, including lack of time, embarrassment, and lack of choice of bridging contraception offered, as well as existing contextual challenges within the pharmacy setting. The retail setting, lack of resources and expanding services emphasise the need for sufficient time and resources to administer bridging adequately to be embedded within routine 'everyday' practice. Recommendations to increase uptake of bridging contraception within the pharmacy setting include greater advertising of the service to raise awareness; flexibility regarding accessing routine contraceptive services within pharmacies (eg, option to book appointments) to overcome time-related barriers; maintenance of non-judgemental and supportive contraceptive consultations to alleviate embarrassment; and the need for future research into the feasibility of offering alternative contraceptive options within the pharmacy context for those resistant to taking POP specifically.

While the incorporation of bridging within the pharmacy setting in Scotland is a step forward in increasing

access to longer-term contraception,¹² it is important to recognise that it is not a comprehensive solution, and acknowledge the potential limitations of this approach. The intervention did not work for all and persistent barriers to accessing and using effective contraception remain, echoed in previous literature,^{18 19 23} including worries about side effects, ingrained stigma relating to accessing contraception particularly within SRH services, and difficulties accessing appointments for continued contraceptive care. Under current regulations, after provision of a bridging supply within community pharmacies, patients in Scotland are directed to their local GP practice or local SRH service for ongoing contraception.¹² Participants' experiences highlight that while bridging within the pharmacy context was key in overcoming initial access barriers to regular contraception, the need to access traditional contraceptive settings (eg, GP, SRH clinics) for ongoing contraception maintained barriers to continuation. For others, barriers to regular uptake of contraception were primarily well-being related, highlighting persistent difficulties faced in contraceptive journeys, and the need for a central focus on well-being within contraceptive consultations. Such challenges should be acknowledged in the design of future contraceptive service trials, and our key recommendations to increase uptake of ongoing contraception include: clear and consistent sign-posting of contraceptive services; key focus on well-being within contraceptive consultations; greater linkage with GP practices; easier processes for obtaining repeat supplies from the pharmacy without the need for a prescription, and consideration of longer-term contraceptive care within the community pharmacy context. Some of these recommendations could be relatively straightforward to implement (eg, continuing professional development course on supportive well-being led consultations), while others would require practice, regulation or policy change. The Scottish government has highlighted a commitment to provision of more routine sexual healthcare, including access to broader contraception services within the pharmacy context.²⁴ It is important to note that the findings from this study are specific to the UK context and implementation in other settings would require consideration of context-specific regulations and contraceptive availability.

Strengths and limitations

Previous evaluations of interventions within the pharmacy context have often focused on exclusively quantitative measures.²⁵ In contrast, The Bridge-it process evaluation combined qualitative and quantitative methods to provide comprehensive and robust insights into implementation of the intervention, mechanisms of change and important contextual factors. There are limitations. As participants were followed up 4 months postintervention, and qualitative interviews were conducted at one time point, we are unable to confidently comment on continuation of the chosen contraceptive method and longer term implementation of the service. Due to practical reasons, direct

observation of pharmacist training sessions only took place at Scottish sites, and we were unable to observe implementation of the intervention in practice within the pharmacy and SRH context, making assessing fidelity difficult. In addition, lack of engagement with the rapid access component and difficulties recruiting SRH clinical staff for interview meant that accounts within the SRH context were limited. While purposive sampling was used to ensure the pharmacists and participants recruited for interview were diverse, it is possible that participants may have been more likely to agree to interview due to particularly positive or negative experiences of the study, and the generalisability of findings are limited to accounts from those who agreed to take part in the trial. It is important to acknowledge that participating pharmacies and pharmacists may be more positive about the intervention than those who did not wish to participate in the study (due to barriers such as existing workload). It should also be noted that pharmacists and participants were being asked to reflect on experiences up to 6 months previously, which may have impacted recall.

Conclusion

Providing a bridging supply of the POP with EC from community pharmacies had positive impacts on contraceptive practices in the short term, and potentially in the longer term through overcoming some of the existing barriers to access and through increasing users' confidence in accessing contraception. The accessibility and convenience of the pharmacy setting was pivotal in making effective contraception more accessible. Implementation appeared to be acceptable, welcomed and feasible to be routinely embedded within pharmacy practice. Lack of engagement with the rapid access component of the intervention and changing SRH service provision suggest that sign-posting to SRH services may be sufficient. If widely implemented, provision of bridging contraception within community pharmacies has the potential to increase access to contraception and prevent more unintended pregnancies for women. Persistent challenges to ongoing contraceptive use should be considered in the design of future contraceptive service trials, and highlight the need for a package of solutions to ensure all needs are met.

Author affiliations

¹MRC/CSO Social and Public Health Sciences Unit, University of Glasgow, Glasgow, UK

²Institute for Social Science Research, The University of Queensland, Brisbane, Queensland, Australia

³School of Social and Political Sciences, University of Glasgow, Glasgow, UK

⁴Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK

⁵Department of Obstetrics and Gynaecology, University of Edinburgh, Edinburgh, UK

⁶Directorate of Public Health, NHS Tayside, Dundee, UK

⁷Division of Cardiovascular Medicines and Diabetes, Ninewells Hospital and Medical School, Dundee, UK

⁸Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, UK

⁹King's College Hospital and King's Centre for Global Health and Health Partnerships, King's College London, London, UK

¹⁰Institute for Global Health, University College London, London, UK

¹¹Sexual and Reproductive Health, NHS Lothian, Edinburgh, UK

Twitter Andrew Radley @AndrRadl and Nicola Stewart @Nicola_stewart_

Acknowledgements The authors would like to thank participating sites, the pharmacists, SRH clinical staff, and participants who took part in interviews, the Bridge-it Study Steering Committee, the Bridge-it Study Patient and Public Involvement Group, research staff involved in implementing the study and Katherine Lewis for excellent project support.

Contributors SP led on data collection and analysis, and on the initial draft of the manuscript. LM was a coinvestigator of the Bridge-it study, and led on the process evaluation, contributing to study design, supervising the project and its staff, and made significant contributions to drafting and revising the manuscript. KS contributed to data collection and analysis, and commented on and approved the final version of the manuscript. AG, AR and JMS were coinvestigators, and contributed to conception and design of the study, and commented on and approved the final version of the manuscript. CB, AJ, AM, DS and NS recruited participants, facilitated data collection, were responsible for day-to-day management of the main study within the three sites, and commented on and approved the final version of the manuscript. STC was the chief investigator and guarantor of the Bridge-it study, and contributed to conception and design of the study, and drafting and revising the manuscript.

Funding Funding for the research was provided by the National Institute for Health Research's Health Technology Assessment Programme. HTA Project: 15/113/01. LM and SP are funded by the UK Medical Research Council and Chief Scientist Office of the Scottish Government Health and Social Care Directorates at the MRC/CSO Social & Public Health Sciences Unit, University of Glasgow (MC_UU_12017/11, SPHSU11; MC_UU_00022/3, SPHSU18).

Disclaimer The views expressed are those of the author(s) and not necessarily those of the NIHR, the NHS or the Department of Health and Social Care.

Competing interests STC reports grants from the National Institute for Health Research (Health Technology Assessment (NIHR HTA) Programme), during the conduct of the study. AG is a consultant to HRA Pharma. AR reports receiving research grants from Gilead Sciences, Bristol-Myers Squibb, AbbVie and Roche; honorariums from Gilead Sciences; and personal fees from AbbVie. AM reports grants from NIHR HTA during the conduct of this study. AM is a clinical support bank midwife for SH:24 and a research midwife at Oxford University. All other authors declare no competing interests.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and was approved by This study was granted ethical approval by the South East Scotland REC in June 2017 (17/SS/0080). Approvals have been obtained from NHS Research Scotland (NRS) and Health Research Authority England (HRA) prior to commencement of the study. Protocol number AC17032IRAS project ID 208918 Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. Access to anonymised data are available on reasonable request. All data requests should be submitted to the Chief Investigator (STC) (Sharon.Cameron@ed.ac.uk) for consideration.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.



ORCID iDs

Susan Patterson <http://orcid.org/0000-0003-1846-5749>
 Lisa McDaid <http://orcid.org/0000-0002-7711-8723>
 Andrew Radley <http://orcid.org/0000-0003-4772-2388>
 Alessandra Morelli <http://orcid.org/0000-0002-9803-2136>
 Sharon Tracey Cameron <http://orcid.org/0000-0002-1168-2276>

REFERENCES

- Public Health Scotland. Termination of pregnancy statistics (year ending December 2020); 2021. <https://publichealthscotland.scot/publications/termination-of-pregnancy-statistics/termination-of-pregnancy-statistics-year-ending-december-2020/> [Accessed January 2022].
- Department of Health and Social Care. Abortion statistics, England and Wales: 2020, 2022. Available: <https://www.gov.uk/government/statistics/abortion-statistics-for-england-and-wales-2020/abortion-statistics-england-and-wales-2020> [Accessed January 2022].
- Wellings K, Jones KG, Mercer CH, *et al.* The prevalence of unplanned pregnancy and associated factors in Britain: findings from the third national survey of sexual attitudes and lifestyles (Natsal-3). *Lancet* 2013;382:1807–16.
- Marston C, Meltzer H, Majeed A. Impact on contraceptive practice of making emergency hormonal contraception available over the counter in Great Britain: repeated cross sectional surveys. *BMJ* 2005;331:271.
- NHS Digital. Sexual and reproductive health services (Contraception), 2018. Available: <https://digital.nhs.uk/data-and-information/publications/statistical/sexual-and-reproductive-health-services> [Accessed Aug 2020].
- Faculty of Sexual and Reproductive Healthcare. Emergency contraception, 2017. Available: <https://www.fsrh.org/documents/ceu-clinical-guidance-emergency-contraception-march-2017/> [Accessed Dec 2020].
- All Party Parliamentary Group on Sexual and Reproductive Health in the UK (APPGSRH). Women's lives, women's rights: strengthening access to contraception beyond the pandemic; 2020. <https://www.fsrh.org/documents/womens-lives-womens-rights-executive-summary/>
- Boog K, Chen ZE, Cameron S. Sexual and reproductive healthcare providers' opinions on expansion of pharmacy-led provision of contraception. *BMJ Sex Reprod Health* 2019;45:183–9.
- Todd A, Copeland A, Husband A, *et al.* Access all areas? an area-level analysis of accessibility to general practice and community pharmacy services in England by urbanity and social deprivation. *BMJ Open* 2015;5:e007328.
- Medicines and Healthcare products Regulatory Agency (MHRA). First progestogen-only contraceptive pills to be available to purchase from pharmacies; 2021. <https://www.gov.uk/government/news/first-progesterone-only-contraceptive-pills-to-be-available-to-purchase-from-pharmacies> [Accessed 01.08.2021].
- Cameron ST, Glasier A, McDaid L. A pragmatic cluster randomised cohort crossover trial to determine use of effective contraception following provision of the progestogen only pill to women presenting to community pharmacies for emergency contraception: the Bridge-it study. *Lancet* 2020;396:1585–94.
- Scottish Government. Supporting women's health, 2021. Available: <https://www.gov.scot/news/supporting-womens-health/> [Accessed December 2021].
- Cameron ST, Baraitser P, Glasier A, *et al.* Pragmatic cluster randomised cohort cross-over trial to determine the effectiveness of bridging from emergency to regular contraception: the Bridge-it study protocol. *BMJ Open* 2019;9:e029978.
- Moore GF, Audrey S, Barker M, *et al.* Process evaluation of complex interventions: Medical Research Council (MRC) guidance. *BMJ* 2015;350:h1258.
- Michie L, Cameron ST, Glasier A, *et al.* Contraceptive use among women presenting to pharmacies for emergency contraception: an opportunity for intervention. *J Fam Plann Reprod Health Care* 2014;40:190–5.
- Michie L, Cameron ST, Glasier A, *et al.* Provision of contraception after emergency contraception from the pharmacy: evaluating the acceptability of pharmacy for providing sexual and reproductive health services. *Public Health* 2016;135:97–103.
- Ritchie J, Spencer L. Qualitative data analysis for applied policy research. In: Bryman A, Burgess R, eds. *The qualitative researcher's companion*. Abingdon: Taylor and Francis, 2002: 53–76.
- Baxter S, Blank L, Guillaume L, *et al.* Views of contraceptive service delivery to young people in the UK: a systematic review and thematic synthesis. *J Fam Plann Reprod Health Care* 2011;37:71–84.
- Free C, Ogden J, Lee R. Young women's contraception use as a contextual and dynamic behaviour: A qualitative study. *Psychol Health* 2005;20:673–90.
- Gale A, Watson MC. The provision of current and future sexual health services from community pharmacies in Grampian, Scotland. *Int J Clin Pharm* 2011;33:183–90.
- Hamidi OP, Deimling T, Lehman E, *et al.* High self-efficacy is associated with prescription contraceptive use. *Womens Health Issues* 2018;28:509–13.
- Poobalan AS, Pitchforth E, Imamura M, *et al.* Characteristics of effective interventions in improving young people's sexual health: a review of reviews. *Sex Educ* 2009;9:319–36.
- Cheung E, Free C. Factors influencing young women's decision making regarding hormonal contraceptives: a qualitative study. *Contraception* 2005;71:426–31.
- Scottish Government. Women's health plan; 2021. <https://www.gov.scot/publications/womens-health-plan/> [Accessed September 2021].
- Parsons J, Adams C, Aziz N, *et al.* Evaluation of a community pharmacy delivered oral contraception service. *J Fam Plann Reprod Health Care* 2013;39:97–101.

Supplementary data

Supplementary data 1: Interview topic guides



Bridge it Process Evaluation – In depth Interview Guides

Pharmacists – Topic Guide

Introduction

General background (1)

- Age (a)
- Life circumstances (i.e. relationships, family etc) (b)
- Employment / education (c)
- Professional backgrounds (d)

Pharmacy information (2)

- Description of pharmacy [*Probe: size, type, location, services provided, typical day*] (a)
- Description of typical EC provision in pharmacy and local area (b)
- Pharmacists' perceptions of women requesting EC [*Probe: positives, negatives, activity, gaps, potential improvement*] (c)
- Previous training in similar interventions (d)

Clarity and consistency of training and Bridge it intervention materials (3)

- How did you find the training? [*Probe: positives, negatives, gaps, potential improvement*] (a)
- What are your views on the training manual? [*Probe: positives, negatives, gaps, potential improvement*] (b)
- Confidence in delivering the Bridge it intervention and adhering to the protocol/training manual [*Probe: positives, negatives, gaps, challenges*] (c)
- Consistency in delivering the Bridge it intervention and adhering to the protocol/training manual [*Probe: If not, when not and why not?*] (d)

Intervention delivery (4)

- Experiences of delivering the intervention and challenges faced (a)
 - Perceived work required to deliver the intervention/trial
 - Barriers/facilitators to delivering the intervention [*Probe: positives, negatives, gaps, potential improvement*]
- Describe how the intervention was introduced and delivered in practice (b)
 - Decision making process – what factors considered in delivering the intervention to individual women?
- From your perspective, how well did the Bridge it intervention fit in with day-to-day pharmacy service provision? (c)
- How well did it fit with current pharmacy guidelines for EC distribution? (d)
- Did it raise any unexpected issues relating to day-to-day pharmacy service provision? (e)

Women's response to the Bridge it intervention (5)


- Perceived facilitators / barriers to women's participation in the Bridge it study [*Probe: positives, negatives, gaps, potential improvement*] (a)
- What, if any, positive effects do you think the Bridge it intervention had? (b)
- What, if any, negative effects do you think the Bridge it intervention had? (c)
- Did anyone refuse to participate? [*Probe: why?*] (d)

Acceptability of the intervention (6)

- What were your reasons for taking part in the intervention? (a)
- What, if anything, did you find particularly positive about being involved in the Bridge it study? (b)
- What, if anything, did you find particularly negative about being involved in the Bridge it study? (c)
- Would you volunteer again for a similar role in the future? [*Probe: why?*] (d)
- How could we improve the pharmacist role? (e)
- Suggested changes to the Bridge it intervention if it were to be more widely implemented? (f)

Other (7)

- Were you aware of any relevant media coverage? (a)
- Impact of changing pharmacy guidelines (b)



Bridge it Process Evaluation – In depth Interview Guides

Bridge it Participants – Topic Guide

Introduction

General background (1)

- Age (a)
- Life circumstances (i.e. relationships, family etc) (b)
- Area of residence, who living with (ie. family, partner, friends, homeless) (c)
- Employment / education (d)

Contraceptive use (2)

- The wider context of their lives and experiences of using EC/contraception (a)
 - Previous experience of EC use / unprotected sex (before/after EC use)
 - Previous contraceptive use
 - Previous pregnancies/abortions
- Decision making process – what kind of things have influenced your contraceptive use, what did you consider when making decisions about contraceptive use? (b)
- Influence of others (i.e. family, friends, healthcare providers etc) (c)
- Partner; family; friends, attitudes to/support for EC/contraceptive use (d)

Request for EC (3)

- Do you mind telling me a bit about why you requested EC at the time of recruitment to the Bridge it study [*Probe: unprotected sex, contraceptive failure, unplanned sex*] (a)
- Decision making process – what factors considered in deciding to use EC? (b)
- Influence of others (i.e. family, friends, healthcare providers etc) (c)
- Decision to attend the pharmacy to request EC – what factors considered in deciding to use EC? (d)
- Why that particular pharmacy? (e)

Recruitment to the Bridge it study (4)

- How were you recruited into the study? (a)
- What did you understand about why we were doing the study? (b)
 - *What it was about?*
 - *Why you were invited to take part?*
- Did you understand what would be involved in taking part? (c)
- What information did the pharmacist provide you with about taking part in the study? [*Probe: verbal, written, other? Was it clear?*] (d)

Reflections on experience of participating in the intervention in pharmacy (5)

- What information did the pharmacist provide you with about starting contraception after EC? [*Probe: verbal, written, other?*] (a)
- What information did the pharmacist provide you with about where to get contraception after EC? [*Probe: verbal, written, other?*] (b)
- What information did the pharmacist provide you with about using the supply of the POP? [*Probe: verbal, written, other?*] (c)
- What information did the pharmacist provide you with about using the 'study card' that participants show at the local sexual health clinic to get a quick appointment? [*Probe: verbal, written, other?*] (d)

Reflections on experience of using EC/POP (6)

- Experience of using the EC that the pharmacist gave you [*Probe: positives, negatives, when?*] (a)
- Experience of using the POP that the pharmacist gave you [*Probe: positives, negatives, when/for how long? If stopped or didn't take it, why?*] (b)
- Decision making process – what factors considered in deciding to use POP? (c)
- Influence of others (i.e. family, friends, healthcare providers etc) (d)

Reflections on experience of accessing SRH service (7)

- Did you attend SRH service after attending the pharmacy for EC? (a)
 - Did you take your Bridge it study card with you? [*Probe: If not, why not?*]
 - What was your experience of the rapid access appointment? [*Probe: positives, negatives, gaps, potential improvement*]
- Decision making process – what factors considered in deciding to attend SRH service? (b)
- Influence of others (i.e. family, friends, healthcare providers etc) (c)

- What information did the SRH provider provide you with about starting effective contraception? [*Probe: verbal, written, other?*] (d)
- Did you start your preferred method of contraception at SRH? [*Probe: If not, why not?*] (e)

Subsequent contraceptive use (8)

- Are you still using the method of contraception you received at SRH? [*Probe: If not, why not, what method are you using now?*] (a)
- From your perspective, what are the barriers/challenges to uptake of effective contraception? (b)

Acceptability of the intervention (9)

- What, if anything, did you find particularly positive about being involved in the Bridge it study? (a)
- What, if anything, did you find particularly negative about being involved in the Bridge it study? (b)
- Did the intervention prompt any change and/or any negative or unintended consequences for you? [*Probe: Any negative outcomes, difficulties, challenges?*] (c)

Implementing the Bridge it intervention (10)

- From your perspective, how well did the Bridge it intervention fit in with your day-to-day life? (a)
- Did it raise any unexpected issues relating to your day-to-day life? (b)
- How could we improve the Bridge it intervention if it were to be more widely implemented? (c)

Other (11)

- Were you aware of any media coverage around contraceptive use/pharmacies? (a)
- Are there any other issues regarding the Bridge it study that you would like to talk about? (b)

Closing

- Provide summary of interview discussion
- Ensure interviewee has opportunity to add comments / ask questions
- Seek feedback on the interview experience

Supplementary data 3: Training observation proforma

PHARMACIST TRAINING OBSERVATIONS

LOCATION: _____ DATE / TIME:

SESSION TYPE: _____

TRAINING VISIT DETAILS	
Who is conducting the training?	
How many pharmacists present?	
How many pharmacists were invited?	

<p>1. FIDELITY:</p> <p>Is the training session delivered as per the training guide/materials?</p> <p>Were all the provided materials used?</p> <p>Were any adaptations made? If so:</p> <ul style="list-style-type: none"> - What - When - By whom - Why 	
<p>2. ACCEPTABILITY:</p> <p>How acceptable to pharmacists does the content of the session appear to be? (e.g. interest; enjoyment; enthusiasm)</p> <p>How acceptable does their role in the intervention appear to be to pharmacists? (e.g. any awkwardness, reluctance, concerns, questions etc)</p> <p>How acceptable generally do pharmacists seem to be about the premise of the intervention?</p> <p>To what degree does the trainer role appear to be acceptable to trainers?</p>	

<p>3. EXPOSURE</p> <p>To what extent do the pharmacists engage in this activity/session? (anyone not involved; excluded or opted out; not engaged)</p> <p>To what extent did participants seem to struggle with receiving or understanding the intervention? (any confusion; not understanding information or task)</p> <p>Were any components of the session not delivered?</p>	
<p>4. CONTEXT</p> <p>Were there any challenges that impacted the delivery of the session?</p> <p>Group dynamics (e.g. dominant individuals, rapport, mixing)</p> <p>Barriers to implementation of the session?</p> <p>Facilitators to implementation of the session?</p> <p>Specific components that did/not work particularly well?</p> <p>Any other contextual factors...</p>	

Supplementary data 4: 4-month follow-up questionnaire

4 Month Questionnaire

BRIDGE-IT Study Trial Number:

We would be very grateful if you would spend some time filling out this anonymous questionnaire. It should take you about 10 minutes. The questionnaire asks about. Completion of this is voluntary and you don't have to answer this questionnaire or any question in it if you don't want to – it is entirely your choice.

Section A. Information at the pharmacy and contraception

1. What method of contraception (if any) were you using at the time when you went to get EC from the pharmacy ? (Please tick)

- None
- Condoms
- Other (please write it here).....

2. Did the pharmacist provide you with any information about starting contraception after EC? (Please tick)

- No
- Verbal information only
- Written information only
- Both written and verbal information

3. Did the pharmacist provide you with any information about where to get contraception ? (Please tick)

- No
- Verbal only
- Written only
- Both written and verbal

4. What method or methods of contraception (if any) are you using now? (Please tick all that apply)

- Combined hormonal contraceptive pill / patch or ring
- Progestogen only pill (mini pill)
- Male condom

- Contraceptive injection 'jag' (Depo Provera or Sayana)
- Implant (Nexplanon)
- Copper Coil/intra-uterine device (IUD)
- Intrauterine system (Mirena or Jaydess)
- Female condom
- Cap/diaphragm
- Partner has been sterilised (vasectomy)
- I have been sterilised
- I am currently pregnant
- Other method of protection-**please write here what this is**
- I am not using any method of contraception (**Please go to question 7**)

5. When did you start using this/these contraceptive method(s)?

(Please tick)

- The same day that I took the EC
- The day after I took the EC
- With the start of my next period after the EC
- Other – please specify the approximate date (dd/mm/yyyy)

6. Where did you get the current method(s) of contraception that you are using from (Please tick all that apply)

- GP clinic
- Family planning/ sexual health clinic
- Other -**please tell us where you got contraception from**

Please go to question 8 now

7. Please tell us why you are not using a method of contraception? (Please tick all that apply)

- Not currently sexually active
- I am worried about** side effects with contraception
- I cannot use contraception due to medical reasons
- I am not decided on what method I want to use

- Difficult to get an appointment for GP or family planning/sexual health clinic appointment
- Difficult to find time to get to GP or family planning/sexual health clinic appointment
- I am trying for a baby
- Other - **please tell us why**.....

8. Have you used EC any further time(s) since entering the study? (Please tick)

- No
- Yes- **please tell us how many times approximately**

Section B. Intervention group only

9. Did you use any of the progestogen only pills (POP) that the pharmacist gave you? (Please tick)

- Yes (Go to question 2)
- No - If not, why not? (**Please tick**)
 - Not with a regular partner
 - Not requiring regular contraception
 - I was worried about possible side effects
 - I didn't understand to use it
 - I preferred to start another method of contraception
 - I have used the POP in the past and it did not agree with me
 - I preferred to see my GP for contraception
 - I preferred to attend a family planning/sexual health clinic for contraception
 - Other - **please tell us why**.....

(Go to question 13)

10. When did you start taking the POP? (Please tick)

- The same day that I took the EC
- The day after I took the EC
- With the start of my next period after the EC
- Other – please specify the approximate date (dd/mm/yyyy)

11. How many packets of the POP did you use? (Please tick)

- less than 1 packet
- 1 packet
- less than 2 packets
- 2 packets
- less than 3 packets
- 3 packets
- I am still taking the POP (go to question 13)

12. If you stopped taking the POP before the 3 packets ran out, what was the MAIN reason for this (Please tick one only)

- I stopped due to side effects.....
- I lost the POP supplies
- I started another method
- Other- **please tell us why**.....

13. Did the pharmacist give you a 'rapid access card' to get an appointment at the local sexual health clinic?

- No (Go to Question 15)
- Yes
- I cannot remember

14. Did you attend this local sexual health clinic for contraception? (Please tick)

- Yes (Go to question15)
- No -if No- Why Not ? (**Please tick all that apply**)
 - Not requiring contraception
 - I preferred to see my GP for contraception
 - I preferred to attend another family planning/ sexual health service for contraception
 - Other - **please tell us why**.....

Go to question 22

15. When did you go to get an appointment at the local sexual health clinic for contraception? (Please tick one only)

- The same day that I took the EC
- The day after I took the EC
- Within 1 month after the EC
- 1 to 2 months after the EC
- 2-3 months after the EC
- 3-4 months after the EC
- Other – please specify the approximate date (dd/mm/yyyy)

16. Did you remember to take your rapid access card to get the appointment at the sexual health clinic? (Please tick)

- Yes
- No if No – were you refused an appointment?
- Yes
- No

17. How long did you wait to be seen at the sexual health clinic ? (Please tick)

- < 30 mins
- < 1 hr
- 1-2 hrs
- Other **please tell us how long you waited approximately**.....

18. Did the sexual health clinic provide you with a method of contraception at that visit?

- Yes
- No

19. Did the sexual health clinic provide you with the method of contraception that YOU preferred at that visit?

- Yes (go to question 19)
- No

If No ...please tell us why the clinic did not provide the method you preferred:

- I cannot use the method that I preferred due to medical/ health reasons
- Not enough staff or time to provide with my preferred method at that visit
- Staff would not provide me with it because I was at risk of pregnancy
- Other - **please tell us why**.....

20. What was the method that you preferred but did not get at the rapid access appointment ? (Please tick)

- Implant (Nexplanon)
- Copper Coil/intra-uterine device (IUD)
- Intrauterine system (Mirena or Jaydess)
- Combined hormonal contraceptive pill / patch or ring
- Progestogen only pill (mini pill)
- Male condom
- Contraceptive injection 'jag' (Depo Provera or Sayana)
- Female condom
- Cap/diaphragm

21. How was the experience of the rapid access system to the sexual health clinic? Please tick)

- Smooth
- Neither /Nor
- Problematic - **please tell us why**.....

22. Have you been pregnant since you entered the study 4 months ago?

- No Go to end
- Yes

if Yes, please tell us about all of the pregnancies you have had since you entered the study 4 months ago (Please tick all that apply)

- I am currently pregnant
- I had a miscarriage
- I had an abortion
- I had an ectopic

Other - **please tell us**.....

23. Below are some questions that ask about your circumstances and feelings around the time you became pregnant. Please think of your current (or most recent) pregnancy when answering the questions below.

In the month that I became pregnant.....

(Please tick the statement which most applies to you):

I/we were not using contraception

I/we were using contraception, but not on every occasion

I/we always used contraception, but knew that the method had failed (i.e. broke, moved, came off, came out, not worked etc) at least once

I/we always used contraception

24. In terms of becoming a mother (*first time or again*), I feel that my pregnancy happened at the.....

(Please tick the statement which most applies to you):

right time

ok, but not quite right time

wrong time

25. Just before I became pregnant.....

(Please tick the statement which most applies to you):

I intended to get pregnant

My intentions kept changing

I did not intend to get pregnant

26. Just before I became pregnant....

(Please tick the statement which most applies to you)

I wanted to have a baby

I had mixed feelings about having a baby

I did not want to have a baby

In the next question, we ask about your partner - this might be (or have been) your husband, a partner you live with, a boyfriend, or someone you've had sex with once or twice.

27. Before I became pregnant....

(Please tick the statement which most applies to you)

- My partner and I had agreed that we would like me to be pregnant
- My partner and I had discussed having children together, but hadn't agreed for me to get pregnant
- We never discussed having children together

28. Before you became pregnant, did you do anything to improve your health in preparation for pregnancy?

(Please tick all that apply)

- Took folic acid
- Stopped or cut down smoking
- Stopped or cut down drinking alcohol
- Ate more healthily
- Sought medical/health advice
- Took some other action, please describe

or

- I did not do any of the above before my pregnancy

Thank you for taking the time to complete this questionnaire. Your participation is much appreciated.

Please indicate how you would like to receive your £20 voucher:

- By phone (please insert number).....
- By email (please insert email).....
- By post (please insert address).....

Supplementary Data 5. Process Evaluation data integration table

	IMPLEMENTATION	MECHANISMS OF IMPACT	CONTEXT
Qualitative interviews	<p>Provider acceptability: bridging seen as important way to develop pharmacy services, overcome access barriers and reduce EC use. EC consultation opportune time. Concerns raised: additional time/workload pressures; fit with existing practices/guidelines. Training: study staff approachable and clear; venue, composition and timing suitable; content and resources adequate. Most felt training prepared them for delivery, could have benefited from pharmacist expertise, role-play, refresher sessions. SRH staff received no formal training, lack of awareness of study.</p> <p>Barriers to participation: research barriers (e.g. confidentiality of data; paperwork); uncertainty about bridging; common barrier lack of time/embarrassment; not wanting to take POP/hormonal contraception. Suggestions to alleviate barriers: option to return/book appointments; more choice of options.</p> <p>Fidelity of delivery (pharmacy): descriptions suggest adherence to protocol, although some fatigue with process. Participants mostly reported positive experiences, and clear/consistent info about accessing further contraception. Confusion around study aim common, and some inconsistencies relating to rapid access component.</p> <p>Fidelity of delivery (SRH centre): Few encountered any Bridge-it participants. Participants mostly described negative experiences (4/5 struggle to get further contraception), reporting lack of awareness, being advised to attend GP, clinics being too busy.</p>	<p>Being approached acted as 'prompt to change barrier contraceptive practices. Helped to overcome existing barriers: avoidance, lack of time, difficulties accessing appointments.</p> <p>Pharmacy setting accessible, convenient, and less embarrassing compared to traditional settings. Other benefits: increased awareness/knowledge of contraception/services; improved confidence in accessing and using contraception.</p> <p>Participants currently on effective contraception: mostly had positive/no-side-effects; found it easy to access further contraception; familiarity. Some on effective contraception post-study had no prior experience on contraception (due to lack of need, access barriers), while a small number had previous negative experiences and found POP suitable.</p> <p>Participants not on effective contraception due to range of reasons: personal circumstances (e.g. not sexually active; no partner; pregnant or planning pregnancy); worries and experiences of side-effects (e.g. prolonged bleeding, mood changes; skin problems); commitment due to busy schedules/forgetting; difficulties accessing GP/SRH clinics or finding time to attend. Side-effects from HC commonly mentioned as barrier post-study, and pre-study. 22 interviewed said not on contraception pre-study due to previous negative experiences.</p> <p>Not being able to get further contraception through pharmacies a barrier; embarrassment/shame of accessing via SRH clinics commonly mentioned.</p>	<p>Pharmacy context: existing challenges common across sites included competing priorities, high workloads, lack of resources, expanding roles. Pressures exacerbated at particular times (e.g. winter - flu clinics take priority). Existing challenges impacted on delivery, with de-prioritisation of screening at busy times. New contraceptive guidelines regarding ellaOne (ulipristal acetate) acted as barrier to delivery for some and concerns were raised about future implementation. Despite challenges, pharmacists typically positive about embedding bridging as a service.</p> <p>SRH context: existing challenges across sites included lack of resources, funding cuts and changing service provision. Services being cut and reshaped: 2 sites moved to triaging, from walk-in to priority access appointments. Changing focus from provision of routine contraception, to young people and specialised services. Some worried participants might be turned away/missed due to lack of fit with practice priorities and lack of resources. Some suggested sending to GP practices instead.</p> <p>Broader cultural context: Most participants did not express being consciously aware of any media coverage about contraceptives. Those who were mostly described seeing coverage relating to the new male contraceptive pill, and articles focusing on negative side-effects and general 'horror stories'. Some did talk about media coverage leading to particular contraceptives potentially getting negative reputations, and how this could impact on decision-making around contraception.</p>
Quantitative data (4-month survey; screening logs)	<p>Fidelity of delivery: 90% (n=178) intervention participants/64% control (n=134) provided with information about accessing further contraception. 54 int participants could not recall being given rapid access card. Most seen at SRH clinic in less than an hour (15/25). 64% (n=16/25) had smooth experience of the rapid access system to study SRH clinic.</p> <p>Acceptability: Most accessed further contraception through GP (n=74/141)/ SRH 21/141. Only 17% attended participating SRH centre, 50% preferred accessing via GP. 32% not provided with preferred method of contraception.</p> <p>Barriers to participation (screening logs): Not willing to give contact details and be followed up 54% (n=264/490); not willing to give identifying data sufficient to allow data linkage with NHS registries 54% (n=262); already using a hormonal method of contraception 32% (n=156); does not require EC 19% (n=93); does not have capacity to give informed consent 13% (n=64).</p>	<p>Uptake of effective contraception: 62% (n=122/98) int participants remained on effective contraception at 4 month follow-up: POP 36% (n=71); Combined pill/patch/ring 14% (n=28); LARC methods 7% (n=13/198). 44% (n=88/198) int participants not on effective contraception at 4-month follow-up.</p> <p>Reasons for not using effective contraception at four months: not currently sexually active 47% (n=27/57); worries about side effects (21% (n=12); not decided on method to be used 16% (n=7); difficult to get appointment for GP or a SRH clinic 14% (n=8); difficult to find time to get to GP or a SRH clinic 11% (n=6). 18% (n=35/198) did not use any POP due to: worries about side-effects 29% (n=10/35); not with regular partner 23% (n=8); not requiring regular contraception (n=7); preferred to start another contraceptive 17% (n=6).</p> <p>For those who took POP, main reason for stopping before supply ran out: side effects 25% (n=40/158); started another method 4% (n=6).</p> <p>10% of intervention participants (n=20/198) had used EC post study in comparison to 18% (n=37/208) of control participants.</p>	

<p>Training observations and pharmacy selection</p>	<p>Location/format of training: most conducted in pharmacies (e.g. consultation/training/break rooms) (n=27), 7 at SRH sites. On average 1-3 pharmacists present, approx 75-80 minutes. Fidelity: consistency across sites, sessions delivered per training guidance mostly, covering all components. Some adaptations, mostly relating to time spent on particular components impacted by contextual factors (e.g. lack of time)</p> <p>Acceptability: majority of pharmacists appeared enthusiastic about the study, engaged well with content, asking for clarification if unsure. Most seemed confident, and accepting of role. Implementation concerns included: lack of staff/resources; volume of paperwork; availability of rapid access appointments. Barriers to participation highlighted in training: reluctance to take POP, lack of time, worries about data confidentiality particularly from younger participants.</p> <p>Pharmacy selection/recruitment: initially approached those with >30 EC p/m, adapted to consider <30 to include more independent pharmacies/increase recruitment. Barriers to selection: low EC; charging for EC; commissioned for bridging; lack of interest; too busy.</p>	<p>Pharmacists' perspectives: sought after service, real demand for easier access through pharmacies, often have patients looking for this service. Highlighted additional benefits: raising awareness of local sexual health clinics, awareness of testing services.</p>	<p>Training sessions at times shed insights into other contextual factors that may influence implementation including the specific pharmacy context, typical clientele and current EC practice/changing guidelines. Pharmacists frequently mentioned high workloads, lack of resources, reliance on locums as potential barriers to delivery.</p>
<p>Monitoring of contemporaneous events/changing guidelines</p>	<p>Contraceptive guidelines: March 2018 new EC guidelines recommending Ullapristol (ellaOne) as first option. If provided no longer eligible for study.</p> <p>October 2018 new weight guidance requiring double dose of levonorgestrel if weighing >75kg.</p>		<p>Contraceptive guidelines: March 2018 new EC guidelines recommending Ullapristol (ellaOne) as first option. If provided no longer eligible for study.</p> <p>October 2018 new weight guidance requiring double dose of levonorgestrel if weighing >75kg.</p> <p>Media coverage of contraception: July 2017-December 2019 736 articles identified from mainstream media sources. Topics included: personal accounts of negative experiences; emerging contraceptive methods (e.g. male contraceptives; contraceptive digital apps); accessibility of contraception (e.g. barriers to access and use); contraceptive behaviour trends; and general informative pieces. Sustained coverage on negative side-effects and personalised 'horror stories' detailing fatal or life-threatening impacts. Over 3 year study period, numbers almost tripled from 35 in 2017 to 94 in 2019. Prominent and relevant story during study period was widespread coverage related to cost and accessibility of the pill within a major chain pharmacy in the UK (n=64). Criticised for refusing to reduce EC cost for fear of "incentivis[ing] inappropriate use".</p>

Researcher fieldnotes/meeting minutes	<p>Initial set-up took longer than anticipated which had consequences for project staffing, pharmacy set-up, training and recruitment. Finalising PGDs and SS for each site time-consuming and problematic, complicated by differences in health boards. Other factors contributing to delays included: changing data protection laws, difficulties organising training sessions particularly in busy restricted periods; and research staffing issues.</p> <p>Research nurses from all sites reported receiving little email response and having to spend a substantial amount of effort on the ground to encourage pharmacists to recruit, to retrain, and to assist with paperwork. Reported evident fatigue with research process.</p> <p>Some major London pharmacies already commissioned for oral bridging.</p>		<p>Pharmacists reported decline in EC requests during the summer and winter holidays, particularly pronounced in areas normally densely populated by students.</p> <p>Slow recruitment fuelled by understaffing, reliance on locums, and other operational challenges (e.g. prioritisation of flu clinics) Protocol amendment submitted to allow new weight guidance to be part of study, however changing guidance did cause some confusion and some pharmacists continued to exclude based on new guidance.</p> <p>Due to commissioning of a sexual and reproductive health bid, London site stopped recruiting and participating pharmacies removed from study.</p>
Interpretation and synthesis	<p>The intervention was acceptable to providers and seen as an important way to improve access to contraception and reduce repeat EC use. Training was considered to be satisfactory, although suggested improvements included: drawing on pharmacist expertise, more practice-based learning, and formal refresher training. Pharmacists seemed accepting of their role in the study and felt prepared for delivery, although had some concerns relating to workload pressures. Fidelity of delivery was mostly achieved within the pharmacy context, with typically clear and consistent messaging around accessing further contraception. Accounts highlighted a lack of awareness within SRH centres, and participants reported unsatisfactory experiences, indicating the need for greater integration of all services involved. A variety of barriers to participation were highlighted, some specific to the research context, while others are relevant to wider implementation (e.g. embarrassment, reluctance to take POP).</p>	<p>Bridging may have positive impacts on contraceptive practices and knowledge in short term, and potentially longer term. Potential key mechanisms of change highlighted include ease of access, increased knowledge, awareness, and confidence in accessing contraception and managing risk. A key mechanism specific to pharmacy setting was ease of access. Accounts highlighted the real need and demand for this service suggesting synergy in intervention design and patient need. Persistent barriers to accessing and regularly using routine contraception remain, including worries about side-effects, ingrained stigma of SRH services, and difficulties accessing contraceptive appointments. While the study was effective for some (including non-users and previous users), it is not a comprehensive solution and remaining challenges highlight need for package of solutions to ensure diversity of needs met.</p>	<p>Broad range of contextual factors influenced implementation of the study, including the context of participating pharmacies and SRH centres, broader policy and cultural factors, and the research context. Existing challenges within provider contexts including lack of resources and changing practice priorities influenced implementation of the study, with screening de-prioritisation and participants being missed or turned away from SRH centres. Such existing challenges meant a high-level of in-person study support was required to motivate staff to recruit. Despite challenges, pharmacists were enthusiastic about embedding bridging as routine practice, however, accounts highlight the need for additional resources due to existing time pressures. There was sustained coverage of negative media coverage of contraception during the study period, which may impact on decision-making around participating and contraceptive use. Updated contraceptive guidance impacted on recruitment into the study, and has potential implications for wider implementation in the current format.</p>
Key learning and recommendations	<p>Suggestions to increase uptake of bridging contraception within the pharmacy setting/overcome barriers to participation include: greater advertising and promotion of the service; provision of non-judgemental and supportive contraceptive consultations; an option to book routine contraceptive consultations within pharmacies outwith EC consultations; and increasing the bridging contraceptive options available.</p> <p>Learning for future trials: need for stream-lined process with condensed paperwork; adequate staff for in-person support; integration and regular communication with all services involved in implementation and delivery.</p>	<p>Suggestions to increase continued uptake of effective contraception include: clear and consistent information provision about further contraceptive access; greater linkage with GP practices; easier processes for obtaining repeat prescriptions, and consideration of longer-term contraceptive care within the pharmacy setting.</p>	<p>Existing contextual challenges within the pharmacy, and SRH context, including lack of resources and changing practice priorities highlight the need for sufficient resources and time to administer this service in order to be embedded within routine practice.</p> <p>Challenges in study set-up and implementation highlight the importance of flexibility and adaptability, and the importance of in-person support from study staff throughout.</p>

Supplementary Data 6: Implementation: key findings and example data

IMPLEMENTATION		
Questions	Key findings	Example data
<i>Fidelity</i>		
To what extent was the intervention delivered as intended?	Fidelity of delivery was mostly achieved within the pharmacy context, with typically clear and consistent messaging around accessing further contraception, although some inconsistencies relating to the rapid access component were reported. Accounts highlighted a lack of awareness within SRH centres, and participants reported unsatisfactory experiences, indicating the need for greater integration of all services involved.	<p><i>Qualitative data:</i> Pharmacists descriptions of delivery suggest general adherence to protocol, although highlighted some fatigue with paperwork. Participants mostly reported positive and informative experiences in pharmacy (“the lady who gave me all the advice on it, she was really, really thorough at explaining everything” Participant 15), although some inconsistencies relating to rapid access component (“no I don’t have a card”, Participant 35). Participants who attended SRH service reported lack of awareness, clinics being busy and being advised to attend GP (“I think I spoke to someone who didn’t know what I was talking about [...] she was like make an appointment with your GP” Participant 5).</p> <p><i>Quantitative data:</i> 90% (n=178) intervention participants/64% control (n=134) provided with information about accessing further contraception. 54 intervention participants could not recall being given rapid access card. Most seen at SRH clinic in less than an hour (15/25).</p> <p><i>Observation data:</i> Training consistency across sites, sessions delivered per training guidance covering all components. Some adaptations made, mostly relating to contextual factors (e.g. lack of time).</p> <p><i>Fieldnotes/meeting notes:</i> Reported fatigue with research procedures, not always screening participants.</p>
<i>Acceptability</i>		
Do providers understand their roles and responsibilities clearly?	Pharmacists seemed to be clear on their roles and responsibilities, and felt prepared for delivery, although could have benefitted from more practice-based learning in training. SRH providers received no formal training for the study, and were less clear on their roles and responsibilities.	<p><i>Qualitative data:</i> Providers seemed to be accepting of the intervention, and positive about the benefits of bridging through the pharmacy context. Pharmacists described training to be satisfactory, with study staff approachable and clear; venue, composition and timing suitable; content and resources adequate (“the training was pretty good, pretty informative” Pharmacist 18). SRH providers described a lack of awareness within their services, which waned over time.</p> <p><i>Observation data:</i> Majority of pharmacists observed appeared enthusiastic about the study, engaged well with content, asking for clarification if unsure. Most seemed confident, and accepting of role although implementation concerns included lack of staff/resources; volume of paperwork; availability of rapid access appointments.</p> <p><i>Field/meeting notes:</i> Research nurses from all sites reported receiving little email response and having to spend a substantial amount of effort on the</p>
Do providers accept the intervention and adopt their roles and responsibilities?	The intervention was acceptable to providers and viewed as an important way to improve contraceptive access and reduce EC use. Some concerns were raised relating to additional workload pressures and fit with existing practices/guidelines.	

		ground to encourage pharmacists to recruit, to retrain, and to assist with paperwork.
<i>Participation</i>		
What were the facilitators of and barrier to recruitment and participation?	A variety of barriers to participation were highlighted, some specific to the research context (e.g. confidentiality of data, paperwork), while others are relevant to wider implementation (e.g. embarrassment, reluctance to take POP). Suggestions to facilitate recruitment and alleviate barriers included: option to return/book appointments; more choice of options.	<p><i>Qualitative data:</i> pharmacists reported a variety of barriers to participation encountered, including research-related barriers (“lots of them were concerned about confidentiality, they were scared that I could just share the data with the GP” Pharmacist 3), as well as persistent barriers relating to contraceptive access including embarrassment, and lack of time.</p> <p><i>Quantitative data:</i> main barriers to participation reported in screening logs included 'not willing to give contact details and be followed up' 54% (n=264/490); 'not willing to give identifying data sufficient to allow data linkage with NHS registries' 54% (n=262); 'already using a hormonal method of contraception' 32% (n=156)</p> <p><i>Observation data:</i> pharmacist perceived barriers to participation highlighted in training included reluctance to take POP, lack of time, worries about data confidentiality particularly from younger participants.</p>

Supplementary Data 7: Mechanisms of impact: key findings and example data

MECHANISMS OF IMPACT		
Questions	Key findings	Example data
<i>Experiences of the intervention</i>		
Did participants understand and implement the intervention as intended?	Participants reported mostly informative experiences within the pharmacy context, and recalled clear advice about where to access further contraception. Use of the rapid access component of the intervention was limited, with most accessing further contraception via their GP. There was a lack of understanding about the aim of the study, which may have impacted on decision-making around accessing further contraception, and motivation to do so.	<i>Qualitative data:</i> Participants typically described being provided with clear information about where to access further contraception, although some inconsistencies in information provision. Most described preferring to access further contraception through their GP due to familiarity and stigma related to SRH context. Not uncommon for participants to think the aim of the study was to test out a new contraceptive pill, rather than about increasing access to further routine contraception: "It would be because you're testing out a new drug to give out at pharmacies and GP's" (Participant 10). <i>Quantitative data:</i> 17% of intervention participants attended participating SRH centre, 50% preferred accessing via GP. Most accessed further contraception through GP (n=74/141)/SRH 21/141.
What were participants' experiences of the intervention?	Participants typically reported positive experiences of the study, particularly in the pharmacy context. Those who attended the SRH service described less positive experiences, reporting a lack of awareness, and difficulties accessing the rapid access component.	<i>Qualitative data:</i> Participants mostly reported positive and informative experiences in pharmacy, although some inconsistencies relating to rapid access component (see implementation). Four out of five participants interviewed who attended SRH service struggled to access further contraception, reporting a lack of awareness, clinics being busy and being advised to attend GP ("so waiting for two hours and being a working individual where clinics aren't open 24 hours either, I just think, you know, some things you just have to bite your tongue with...so to cut a long story short, I'm pregnant" Participant 29). <i>Quantitative data:</i> Most seen at SRH clinic in less than an hour (15/25). 64% (n=16/25) had smooth experience of the rapid access system to study SRH clinic. 32% who attended SRH service not provided with preferred method of contraception.
<i>Impacts on contraceptive practices</i>		
Did the delivered intervention produce change? If so, what were the mechanisms of change?	Bridging may have positive impacts on contraceptive practices and knowledge in short term, and potentially longer term. Key mechanisms of change highlighted include ease of access, increased knowledge, awareness, and confidence in accessing contraception and managing risk.	<i>Quantitative data:</i> 62% (n=122/98) int participants remained on effective contraception at 4 month follow-up: POP 36% (n=71); Combined pill/patch/ring 14% (n=28); LARC methods 7% (n=13/198). <i>Qualitative data:</i> Being approached acted as 'prompt to change contraceptive practices, and helped overcome existing barriers (e.g. avoidance, lack of time, difficulties accessing appointments). Pharmacy setting was viewed as accessible, convenient and discreet ("I think every

<p>What were the facilitators of and barriers to uptake of effective contraception?</p>	<p>Persistent barriers to accessing and regularly using routine contraception remain, including worries about side-effects, ingrained stigma of SRH services, and difficulties accessing contraceptive appointments.</p>	<p>pharmacy has a little room for you to go in, and it's quite discreet" Participant 19). Participants discussed additional benefits including increased knowledge and confidence.</p> <p>Quantitative data: Reasons for not using effective contraception at four months: not currently sexually active 47% (n=27/57); worries about side effects (21% (n=12); not decided on method to be used 16% (n=7); difficult to get appointment for GP or a SRH clinic 14% (n=8); difficult to find time to get to GP or a SRH clinic 11% (n=6). 18% (n=35/198) did not use any POP due to: worries about side-effects 29% (n=10/35); not with regular partner 23% (n=8); not requiring regular contraception (n=7); preferred to start another contraceptive 17% (n=6). For those who took POP, main reason for stopping before supply ran out: side effects 25% (n=40/158); started another method 4% (n=6).</p> <p>Qualitative data: Participants currently on effective contraception typically described having positive/no-side-effects; and found it easy to access further contraception. Participants described a range of barriers to uptake of effective contraception including personal circumstances, perceived/actual side-effects; commitment; and difficulties accessing GP/SRH clinics. Not being able to get further contraception through pharmacies a barrier; embarrassment/shame of accessing via SRH clinics commonly mentioned.</p>
---	--	---

Supplementary Data 8: Context: key findings and example data

CONTEXT		
Questions	Key findings	Example data
<i>Local context</i>		
How did the local context impact on implementation and outcomes?	<p>A range of cross-cutting contextual challenges were identified within the local pharmacy and SRH context including lack of resources and changing practice priorities.</p> <p>Existing challenges within provider context impacted on implementation of the study with screening de-prioritisation and participants being missed or turned away from SRH centres. A high-level of in-person study support was required to motivate staff to recruit. Despite challenges, pharmacists were enthusiastic about embedding bridging as routine practice.</p>	<p><i>Qualitative data:</i> Pharmacists described existing challenges including competing priorities, high workload and lack of resources. Existing challenges impacted on delivery in pharmacy context with de-prioritisation of screening at busy times. Existing challenges in SRH context included lack of resources, funding cuts and changing service provision. SRH workers worried participants might be turned away due to existing challenges, and suggested study should be redesigned to refer to GPs (“I mean perhaps them going to a general practice setting would be more appropriate than directing them to sexual health, given the situation that sexual health is in nowadays, if you know what I mean. Because it is a bit more of a specialist service” SRH worker 3).</p> <p><i>Observation data:</i> Training sessions shed light into other contextual factors that may influence implementation. Pharmacists frequently mentioned high workloads, lack of resources, reliance on locums as potential barriers to delivery.</p> <p><i>Field/meeting notes:</i> Pharmacists reported decline in EC requests during the summer and winter holidays, particularly pronounced in areas normally densely populated by students. Slow recruitment fuelled by understaffing, reliance on locums, and other operational challenges (e.g. prioritisation of flu clinics).</p>
<i>Broader context</i>		
How might the broader context have impacted on outcomes/implementation?	<p>There was sustained negative coverage of contraception during study period within the media, which may have impacted on decision-making around participating in the study, and contraceptive use.</p> <p>A number of key contraceptive guidelines were updated during the study period which impacted on recruitment into the study, and requires consideration for wider implementation in current format.</p>	<p><i>Monitoring of contemporaneous events data (media):</i> July 2017 – December 2019 736 articles identified from mainstream media sources. Sustained coverage on negative side-effects and personalised ‘horror stories’ detailing fatal or life threatening impacts. Over 3 year study period, numbers almost tripled from 35 in 2017 to 94 in 2019. Prominent and relevant story during study period was widespread coverage related to cost and accessibility of EC within a major chain pharmacy in the UK (n=64).</p> <p><i>Monitoring of contraceptive guidelines:</i> March 2018 new EC guidelines recommending Ullapristol (ellaOne) as first option. If provided no longer eligible for study. October 2018 new weight guidance requiring double dose of levonorgestrel if weighing >75kg.</p>

		<p><i>Qualitative data:</i> Most participants did not express being consciously aware of any media coverage about contraceptives. Those who were mostly described seeing coverage relating to the new male contraceptive pill, and articles focusing on negative side-effects and general ‘horror stories’. Some did talk about media coverage leading to particular contraceptives potentially getting negative reputations, and how this could impact on decision making around contraception (“there’s a lot of horror stories out there and I didn’t know if it was the right thing for me to start taking” (Participant 1). New contraceptive guidelines acted as a barrier to delivery for some pharmacies and concerns were raised about wider implementation (“I think with the push towards ellaOne, that’ll kind of throw a spanner in the works for this idea” (Pharmacist 21).</p>
--	--	--